Genetic Testing in Prostate Cancer - PubMed

Genetic Testing in Prostate Cancer - PubMed

Genetic Testing in Prostate Cancer

Alexandra O Sokolova 1 2 3, Heather H Cheng 4 5

Affiliations 

• PMID: 31974718
 
• DOI: 10.1007/s11912-020-0863-6

Abstract

Purpose of review: This review summarizes recent advances in prostate cancer (PCa) genetics.

Recent findings: Upwards of 20% of metastatic castration-resistant prostate tumors (mCRPC) carry homologous recombination (HR) repair gene mutations, of which ~ 10% are germline (inherited). Another ~ 5% exhibit microsatellite instability (MSI-H) and/or mismatch repair deficiency (MMRd). Pembrolizumab is approved for tumors with MMRd, thus patients with mCRPC and MMRd are candidates for pembrolizumab. Emerging data indicate that platinum chemotherapy and poly ADP-ribose polymerase inhibitors (PARPi) are effective in PCa exhibiting HR deficiency. NCCN guidelines now recommend germline and somatic tumor testing in specific clinical scenarios due to treatment and family implications. Genetic testing in PCa patients may inform prognosis, treatment options, and have implications for family counseling. PARPi, platinum chemotherapy, and immune checkpoint inhibitors are promising targeted therapies for PCa with specific molecular features. Therapeutic advances, along with importance to relatives, are driving genetic testing in prostate cancer.

Keywords: BRCA; Genetics; Germline testing; PARPi; Prostate cancer.

Similar articles

• Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

  JJ Adashek et al. Cells 8 (8). 2019. PMID 31404966. - Review

  The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant pros …
• Role of BRCA Mutations in Cancer Treatment With Poly(ADP-ribose) Polymerase (PARP) Inhibitors

  I Faraoni et al. Cancers (Basel) 10 (12). 2018. PMID 30518089. - Review

  Inhibition of poly(ADP-ribose) polymerase (PARP) activity induces synthetic lethality in mutated BRCA1/2 cancers by selectively targeting tumor cells that fail to repair …
• Treatment Strategies for DNA Repair-Deficient Prostate Cancer

  BA Teply et al. Expert Rev Clin Pharmacol 10 (8), 889-898. Aug 2017. PMID 28573914. - Review

  Common recurrent genetic alterations have been identified in prostate cancer through comprehensive sequencing efforts, and the prevalence of mutations in DNA repair pathw …
• Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations

  BA Carneiro et al. JCO Precis Oncol 2. 2018. PMID 31501807.

  PARP1/2 inhibitors are effective against BRCA2-deficient tumors. The PARP inhibitor (PARPi) olaparib received FDA breakthrough designation for treatment of metastatic cas …
• The Importance of Distinguishing Sporadic Cancers From Those Related to Cancer Predisposing Germline Mutations

  S Sorscher. Oncologist 23 (11), 1266-1268. Nov 2018. PMID 29866945.

  Choosing the optimal therapy for a patient's cancer has long been based on whether the cancer demonstrates a predictive marker of efficacy. The U.S. Food and Drug Adminis …